MCL1 inhibitors S63845/MIK665 plus Navitoclax synergistically kill difficult-to-treat melanoma cells

Current treatment for patients with metastatic melanoma include molecular-targeted therapies and immune checkpoint inhibitors. However, a subset of melanomas are difficult-to-treat. These melanomas include those without the genetic markers for targeted therapy, non-responsive to immunotherapy, and t...

Descripción completa

Detalles Bibliográficos
Autores principales: Mukherjee, Nabanita, Skees, Jenette, Todd, Kaleb J., West, Drake A., Lambert, Karoline A., Robinson, William A., Amato, Carol M., Couts, Kasey L., Van Gullick, Robert, MacBeth, Morgan, Nassar, Kelsey, Tan, Aik-Choon, Zhai, Zili, Fujita, Mayumi, Bagby, Stacey M., Dart, Chiara R., Lambert, James R., Norris, David A., Shellman, Yiqun G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7280535/
https://www.ncbi.nlm.nih.gov/pubmed/32513939
http://dx.doi.org/10.1038/s41419-020-2646-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7280535/
https://www.ncbi.nlm.nih.gov/pubmed/32513939
http://dx.doi.org/10.1038/s41419-020-2646-2

Ejemplares similares